GlassScriptPhysician profile
Lynn M Mcclintock
NPI 1366411282
$917.00
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $245 · 2021: $11.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $432.27 | 2019-2020 | |
| Amgen INC. | $115.64 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.84 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $71.37 | 2019 | |
| Lilly USA, LLC | $39.62 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $33.68 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.99 | 2019-2020 | |
| Radius Health, INC. | $22.49 | 2019 | |
| Allergan, INC. | $15.75 | 2019 | |
| Chiesi USA, INC. | $14.05 | 2019 | |
| Glaxosmithkline, LLC. | $14.01 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.15 | 2019 | |
| Merck Sharp & Dohme LLC | $11.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Mcclintock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.